drugset

drugset / Trial / NCT02997163

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

NCT02997163 ↗

Phase 1 Completed 34 enrolled Pfizer Medivation, Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial will investigate the pharmacokinetics (PK) and safety of talazoparib in patients with advanced solid tumors and impaired renal function.

Timeline

Start: 2017-02-21
Primary completion: 2019-01-30
Completion: 2019-01-30

Publications

Durairaj C, Chakrabarti J, Ferrario C, Hirte HW, Babu S, Piha-Paul SA, Plotka A, Hoffman J, Shi H, Wang DD. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. Clin Pharmacokinet. 2021 Jul;60(7):921-930. doi: 10.1007/s40262-020-00983-y. Epub 2021 Mar 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Talazoparib	Small molecule	0.5 mg	Oral

Indications